lexapro has been researched along with galantamine in 1 studies
| Studies (lexapro) | Trials (lexapro) | Recent Studies (post-2010) (lexapro) | Studies (galantamine) | Trials (galantamine) | Recent Studies (post-2010) (galantamine) |
|---|---|---|---|---|---|
| 17 | 0 | 12 | 1,874 | 209 | 703 |
| Protein | Taxonomy | lexapro (IC50) | galantamine (IC50) |
|---|---|---|---|
| Chain A, ACETYLCHOLINESTERASE | Tetronarce californica (Pacific electric ray) | 0.652 | |
| Chain A, Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.36 | |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 2.0401 | |
| Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.488 | |
| Cholinesterase | Homo sapiens (human) | 5.4792 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.59 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 2.29 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.8484 | |
| Acetylcholinesterase | Bos taurus (cattle) | 4.53 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 8.3973 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.59 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.59 | |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | 0.8006 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 3.2 | |
| Cholinesterase | Equus caballus (horse) | 7.2215 | |
| Carboxylic ester hydrolase | Equus caballus (horse) | 8.4178 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for lexapro and galantamine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |